Published in Breast Cancer Res Treat on March 01, 1999
Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A (2001) 1.97
Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. J Clin Invest (2009) 1.37
Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res (2009) 1.08
Perspectives on the chemical etiology of breast cancer. Environ Health Perspect (2002) 1.06
Medical mistrust influences black women's level of engagement in BRCA 1/2 genetic counseling and testing. J Natl Med Assoc (2013) 1.04
Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation of bax expression. Nucleic Acids Res (2006) 0.97
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest (2016) 0.94
Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol (2001) 0.92
Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer (2000) 0.91
Methylenetetrahydrofolate reductase gene C677T polymorphism and breast cancer risk: Evidence for genetic susceptibility. Meta Gene (2015) 0.84
New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines. Breast Cancer Res (2005) 0.81
Methylenetetrahydrofolate Reductase A1298C Polymorphism and Breast Cancer Risk: A Meta-analysis of 33 Studies. Ann Med Health Sci Res (2014) 0.78
Breast cancer (1) N Engl J Med (1992) 4.79
Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell (1987) 3.45
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol (1992) 3.15
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep (1985) 2.97
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst (1998) 2.85
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev (1987) 2.07
Mechanism of action of glucocorticoids. Metabolism (1974) 2.04
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science (1990) 2.00
Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res (1978) 1.97
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol (1992) 1.89
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation. Breast Cancer Res Treat (1983) 1.80
Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol (1987) 1.72
Breast conservation versus mastectomy: distress sequelae as a function of choice. J Clin Oncol (1989) 1.70
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol (1989) 1.65
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther (2001) 1.64
Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A (1987) 1.61
Breast cancer risk in rats fed a diet high in n-6 polyunsaturated fatty acids during pregnancy. J Natl Cancer Inst (1996) 1.60
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol (1988) 1.59
Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res (1986) 1.58
Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res (1990) 1.57
Oestrogen-responsive human breast cancer in long term tissue culture. Nature (1975) 1.56
The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med (1978) 1.54
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res (1987) 1.54
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst (2000) 1.46
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science (1986) 1.41
Breast cancer (2). N Engl J Med (1992) 1.39
Growth factors in breast cancer. Endocr Rev (1995) 1.37
Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res (1991) 1.36
Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res (1979) 1.35
Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer (1980) 1.34
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A (1976) 1.32
Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res (1993) 1.32
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res (1993) 1.32
Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res (1988) 1.32
Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen-resistant sublines. J Biol Chem (1984) 1.31
Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol (1988) 1.31
Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst (1993) 1.30
Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep (1979) 1.27
Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst (2001) 1.26
Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science (1985) 1.26
Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res (1999) 1.26
Oestrogen receptors in human malignant melanoma. Lancet (1976) 1.26
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res (1999) 1.25
Expression and function of angiopoietin-1 in breast cancer. Br J Cancer (2000) 1.24
Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis (1994) 1.24
Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res (2001) 1.23
Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci U S A (1987) 1.22
Competitive protein binding assay for methotrexate. Proc Natl Acad Sci U S A (1975) 1.21
Tamoxifen retinopathy. Cancer Treat Rep (1978) 1.21
Effect of estrogens and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res (1985) 1.20
Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology (1985) 1.20
Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology (1986) 1.19
Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc Natl Acad Sci U S A (1989) 1.19
Breast cancer (3). N Engl J Med (1992) 1.18
Glucocorticoid-binding proteins in human acute lymphoblastic leukemic blast cells. J Clin Invest (1973) 1.17
Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem (1982) 1.17
High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. N Engl J Med (2000) 1.17
Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer (1980) 1.15
Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol (1987) 1.14
Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res (1993) 1.14
MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res (1994) 1.14
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol (1989) 1.14
Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol (1992) 1.13
Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res (1983) 1.13
Steroid hormone receptors in normal human lymphocytes. Induction of glucocorticoid receptor activity by phytohemagglutinin stimulation. J Biol Chem (1977) 1.13
Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res (1995) 1.12
Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene (1997) 1.12
Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res (1993) 1.12
Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. Cancer Res (1993) 1.12
The EGF receptor system as a target for antitumor therapy. Cancer Invest (1991) 1.11
Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer (1999) 1.11
8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat (1986) 1.11
Melatonin increases oestrogen receptor binding activity of human breast cancer cells. Nature (1983) 1.11
Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equal three? Breast Cancer Res Treat (1983) 1.10
Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol (1985) 1.09
Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res (1978) 1.09
Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med (1983) 1.09
Control of human breast cancer by estrogen, growth factors, and oncogenes. Cancer Treat Res (1988) 1.08
A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J Biol Chem (1992) 1.08
Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res (2000) 1.07
17 beta-estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci U S A (1986) 1.07
Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol (1986) 1.07
Autocrine and paracrine growth regulation of human breast cancer. J Steroid Biochem (1986) 1.06
ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res (1989) 1.06
Production of and responsiveness to transforming growth factor-beta in normal and oncogene-transformed human mammary epithelial cells. Cancer Res (1989) 1.05
Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. J Biol Chem (1981) 1.04
Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol (1989) 1.03
Evaluation of tamoxifen dose in advanced breast cancer: a progress report. Cancer Treat Rep (1976) 1.01
Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice. Cancer Res (1983) 1.01
The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res (1993) 1.01
A quantitative study of muramidase distribution in normal and nitrogen mustard-treated rats. Yale J Biol Med (1972) 1.01
Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci U S A (1992) 1.00
Steroid hormone receptors in human colon cancers. Cancer (1979) 1.00